Harvard Bioscience, Inc. · LSX:A423J5

Harvard Bioscience, Inc. financial statements

Harvard Bioscience, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue86.5M94.1M112.3M113.3M118.9M102.1M116.2M120.8M77.4M104.5M
Cost of revenue36.6M39.4M46.2M52.5M51.3M44.1M51.9M57.6M38.2M56.1M
Gross profit49.9M54.8M66.1M60.8M67.7M58.0M64.3M63.2M39.2M48.4M
Research and development8.82M10.4M11.8M12.3M10.8M8.69M10.7M11.0M5.64M5.39M
Selling, general and administrative17.7M21.5M22.8M24.5M24.3M23.5M22.8M21.4M18.6M20.9M
Operating income-48.6M-6.21M1.89M-6.93M2.07M221.0K377.0K984.0K-635.0K-3.00M
Depreciation and amortization1.74M1.73M1.47M1.45M1.78M1.92M1.99M2.42M1.32M1.53M
EBITDA-46.8M-4.48M3.37M-5.48M3.85M2.14M2.36M3.41M682.0K-1.47M
Interest expense1.30M800.0K3.59M2.55M1.54M4.83M5.41M5.37M713.0K639.0K
Income before tax-57.4M-11.7M-2.56M-9.18M-140.0K-7.29M-5.50M-7.97M-2.62M-3.08M
Income tax-686.0K740.0K859.0K337.0K148.0K518.0K-815.0K-3.68M-605.0K1.23M
Net income-56.7M-12.4M-3.42M-9.52M-288.0K-7.81M-4.69M-2.92M-865.0K-4.31M
Earnings per share, basic-1.28-0.28-0.08-0.23-0.01-0.20-0.12-0.08-0.02-0.13
Earnings per share, diluted-1.28-0.28-0.08-0.23-0.01-0.20-0.12-0.08-0.02-0.13

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents8.61M4.11M4.28M4.51M7.82M8.32M8.34M8.17M5.73M5.60M
Short-term investments00
Receivables16.0M14.9M16.1M16.7M21.8M17.8M20.7M21.5M13.4M15.7M
Inventory20.8M23.2M24.7M26.4M27.6M22.3M22.1M25.1M16.8M20.0M
Current assets48.2M45.1M49.0M51.1M61.6M51.7M53.6M57.8M47.5M45.5M
Property, plant and equipment4.79M5.11M3.98M3.37M3.42M3.96M4.78M5.90M3.74M4.30M
Goodwill9.56M56.3M57.1M56.3M57.7M58.6M57.4M57.3M36.3M38.0M
Total assets80.1M126.6M137.4M145.4M162.3M156.3M164.9M168.6M109.4M107.8M
Accounts payable3.65M4.79M5.55M6.45M4.91M5.97M5.34M7.36M4.41M6.20M
Current liabilities22.0M55.0M26.5M23.2M25.3M21.1M25.3M25.5M14.0M14.6M
Long-term debt35.9M030.7M43.0M45.1M46.3M46.9M54.8M8.98M11.4M
Total debt35.9M37.0M37.0M46.8M48.3M48.0M53.8M60.8M11.9M13.8M
Total liabilities66.3M63.3M64.3M73.1M78.9M79.6M83.2M85.9M28.5M35.6M
Shareholders' equity13.7M63.3M73.1M72.2M83.4M76.7M81.7M82.7M80.9M72.2M
Shares outstanding4.47M44.1M43.4M42.1M41.1M39.4M38.2M37.4M35.0M35.0M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations6.73M1.44M14.0M1.15M1.26M9.33M8.04M2.88M1.06M5.38M
Capital spending-1.26M-2.64M-1.79M-1.59M-1.20M-1.15M-1.22M-986.0K-890.0K-1.48M
Free cash flow5.47M-1.20M12.2M-438.0K67.0K8.18M6.83M1.90M167.0K3.90M
Cash from investing-1.86M-1.34M-1.80M-1.59M-1.34M-1.40M-229.0K-53.8M-917.0K-62.0K
Cash from financing-1.29M-131.0K-12.1M-2.84M-252.0K-7.97M-7.62M53.1M-1.79M-4.87M
Dividends paid-1.63M-200.0K-221.0K00
Share buybacks-577.0K-2.52M-1.63M-3.51M-1.14M-221.0K4.56M160.0K182.0K
Change in cash4.51M-175.0K-225.0K-3.31M-496.0K-18.0K162.0K2.44M137.0K-1.15M